Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi jump­starts ef­fort to sup­ply 30 'essen­tial' drugs to low­er-in­come coun­tries

A week af­ter Sanofi promised to cut in­sulin prices, the phar­ma gi­ant’s non­prof­it unit is of­fer­ing more de­tails on its ef­fort to make the life-sav­ing drug and 29 oth­ers avail­able to 40 low­er-in­come coun­tries.

To­geth­er, the med­i­cines will form what Sanofi calls the Im­pact brand. They cov­er a range of dis­eases, from di­a­betes to car­dio­vas­cu­lar dis­ease to can­cer, and are con­sid­ered es­sen­tial by the World Health Or­ga­ni­za­tion, the com­pa­ny said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.